Press 
Releases 

Organ-specific, AI-ready multi-omics platform validated for liver disease diagnostics and monitoring

Reflects the potential of EvoLiver™ test to improve early liver cancer detection among high-risk patients

EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …

Mursla Bio was selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics …

Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients